{
    "eid": "2-s2.0-85087032230",
    "title": "Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice",
    "cover-date": "2020-08-23",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "Chimeric antigen receptor T cell (CAR T cell)",
        "immunotherapy",
        "leukemia",
        "lymphoma"
    ],
    "authors": [
        "Kitsada Wudhikarn",
        "Jae H. Park"
    ],
    "citedby-count": 6,
    "ref-count": 84,
    "ref-list": [
        "Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation",
        "International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia",
        "Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study",
        "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia",
        "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma",
        "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma",
        "A milestone for CAR T cells",
        "Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience",
        "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial",
        "2-year follow-up and high-risk cubset analysis of zuma-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma",
        "Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL",
        "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial",
        "Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia",
        "Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia",
        "Toxicities of chimeric antigen receptor T cells: recognition and management",
        "The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden",
        "Determinants of response and resistance to CAR T cell therapy",
        "Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia",
        "Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion",
        "Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas",
        "Cytokine release syndrome and neurotoxicity by baseline tumor burden in adults with relapsed or refractory diffuse large b-cell lymphoma treated with tisagenlecleucel",
        "Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy",
        "Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy",
        "Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma",
        "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification",
        "The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells",
        "Target antigen density governs the efficacy of anti-CD20-CD28-CD3 \u03b6 chimeric antigen receptor-modified effector CD8+ T cells",
        "Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T",
        "CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy",
        "Correlation of pre-CAR CD19 expression with responses and relapses after CAR T cell therapy",
        "CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy",
        "Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy",
        "Multiplexed immunofluorescence (IF) analysis and gene expression profiling of biopsies from patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with lisocabtagene maraleucel (liso-cel) in transcend NHL 001 reveal patterns of immune infiltration associated with durable response",
        "Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin\u2019s lymphoma",
        "Conditioning prior to CAR T cells predicts response and survival in pediatric/young adult relapse/refractory (R/R) B-ALL",
        "Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia",
        "Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells",
        "Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the Juliet trial",
        "Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo",
        "CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients",
        "Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed",
        "High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients",
        "Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor",
        "High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): a defined composition CD19-directed CAR T-cell product with potential for outpatient administration",
        "Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma",
        "A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma",
        "JCARH125, Anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE)",
        "Chimeric-antigen-receptor (CAR) T cells and the factors influencing their therapeutic efficacy",
        "A human memory T cell subset with stem cell-like properties",
        "Superior T memory stem cell persistence supports long-lived T cell memory",
        "Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL",
        "Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies",
        "Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15",
        "Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia",
        "CD19 CAR T cell product and disease attributes predict leukemia remission durability",
        "Upregulation of senescent/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed/refractory B cell malignancies",
        "Influence of CD27- CD28- T-cells on the therapeutic outcome in adult patients with relapsed or refractory diffuse large B-cell lymphoma after CART-infusion",
        "Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy",
        "Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-Cell lymphoma (R/R DLBCL)",
        "CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma",
        "CAR T cells find strength in polyfunction",
        "Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL",
        "Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells",
        "Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function",
        "Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin\u2019s lymphoma",
        "The pharmacology of T cell therapies",
        "Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia",
        "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia",
        "Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia",
        "Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy",
        "Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy",
        "Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies",
        "Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia",
        "CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date",
        "T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma",
        "Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL",
        "Radiation priming chimeric antigen receptor T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma with high tumor burden",
        "Biomarkers of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with chronic lymphocytic leukemia",
        "Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels",
        "A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia",
        "Patient characteristics and pre-infusion biomarkers of inflammation correlate with clinical outcomes after treatment with the defined composition, CD19-targeted CAR T cell product",
        "Exploring the emerging role of the microbiome in cancer immunotherapy",
        "Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma",
        "Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy"
    ],
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "New York",
            "@id": "108088405",
            "affilname": "Cornell College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/108088405",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "National Comprehensive Cancer Center",
        "Conquer Cancer Foundation of ASCO",
        "American Society of Hematology",
        "Leukemia and Lymphoma Society",
        "Geoffrey Beene Cancer Foundation"
    ]
}